Strategic Agreement and Transaction with DHL Group

Strategic Partnership with DHL Group - Cryoport is strategically pivoting to enable the next phase of global Cell and Gene Therapy (CGT) expansion by leveraging DHL's network[5] - The partnership with DHL provides a more competitively priced, integrated solution to the CGT market, especially in the APAC and EMEA regions[5] - The transaction with DHL generates substantial cash and strengthens Cryoport's balance sheet, improving revenue growth rate and gross margin profile[5] Financial Highlights and Projections - Cryoport's new FY 2025 revenue guidance is projected to be between $165 million and $172 million, representing a 6%-10% year-over-year growth[35, 36] - Investments into CGT rose to $15.2 billion in 2024, a 30% year-over-year increase[25] - The divestiture of the specialty courier business to DHL Group yielded $195 million in cash (Enterprise Value), a 2.7x multiple of FY'24 revenue[33] CGT Market and Cryoport's Position - The number of Cell & Gene Therapies approved in FY2024 was 8[15] - Cryoport's clinical trial market share has increased to 70%[15] - Commercial Cell & Gene Therapies revenue reached $26 million[20]